Compare IDEXX Laboratories, Inc. (IDXX) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Quantumscape Corp — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Quantumscape Corp trades at $4.58 (market cap $2.82B). The key difference: IDEXX Laboratories, Inc. is far larger — about 14.3× Quantumscape Corp's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 21,878,246). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Quantumscape Corp for 37 Days on average.
| IDXX | QS | |
|---|---|---|
Market Cap | $40.43B | $2.82B |
Volume | 692,164 | 21,878,246 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $18.44 |
52-Week Low | $504.70 | $4.52 |
Typical Hold Time | 46 Days | 37 Days |
Enterprise Value | $41.32B | $2.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
QuantumScape (QS) trades at $4.58, up 1.33% with bearish technical signals and negative profitability metrics. The company remains pre-revenue with significant cash burn, though recent earnings beat expectations. Analyst consensus shows 72.7% hold ratings with a $10.35 price target, while insider selling and delayed commercialization timelines create headwinds.
QS faces substantial execution risk with commercialization not expected until 2029, but maintains automotive partnerships and pilot production progress. The stock trades near 52-week lows, offering potential upside to analyst targets if technology milestones are achieved, though high cash burn and competitive threats remain key concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
